Skip to main content

FDA grants tentative approval to Teva’s generic Uroxatral


ROCKVILLE, Md. The Food and Drug Administration has given tentative approval to Teva Pharmaceutical Industries' generic version of Sanofi-Aventis’ Uroxatral, FDA records show.

The agency granted the tentative approval to Teva’s alfuzosin hydrochloride extended-release tablets in the 10 mg strength. Alfuzosin hydrochloride is used to treat enlarged prostate.

Uroxatral is a once-daily version of Xatral, which had global sales of $439.2 million in 2007, according to Sanofi-Aventis financial records. Sanofi sued Teva and other generics companies in September 2007 when they sought FDA approval for generic versions of Uroxatral.

This ad will auto-close in 10 seconds